| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Wednesday’s Close |
|---|---|---|---|---|---|
| MRK | Merck & Company, Inc. | $70.42 | $187.28B | N/A |
Blueprint Medicines Posts Data From NSCLC Study on Pralsetinib
http://www.zacks.com/stock/news/709860/blueprint-medicines-posts-data-from-nsclc-study-on-pralsetinib?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-709860
Jan 09, 2020 - Blueprint Medicines (BPMC) posts top-line data from phase I/II study on pralsetinib to treat previously treated patients with RET-fusion NSCLC. Also, it initiates the rolling NDA submission to FDA.
0
Merck's Keytruda Gets FDA Nod for High-Risk Bladder Cancer
http://www.zacks.com/stock/news/709625/mercks-keytruda-gets-fda-nod-for-high-risk-bladder-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-709625
Jan 09, 2020 - Merck's (MRK) Keytruda gets FDA's approval to treat certain patients with high-risk, non-muscle invasive bladder cancer.
0
Merck's Blockbuster Drug Wins Key New FDA Approval
https://www.fool.com/news/2020/01/08/mercks-blockbuster-drug-wins-key-new-fda-approval.aspx?source=iedfolrf0000001
Jan 08, 2020 - Keytruda is now permitted for use in treating an aggressive form of bladder cancer.
0
The Risk of Cancer-Related Death Is Dropping Faster Than Ever
https://www.fool.com/investing/2020/01/08/the-risk-of-cancer-related-death-is-dropping-faste.aspx?source=iedfolrf0000001
Jan 08, 2020 - Finally some good news from the American Cancer Society.
0
3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2020
http://www.zacks.com/stock/news/707821/3-pharma-biotech-pipeline-areas-to-keep-an-eye-on-in-2020?cid=CS-ZC-FT-analyst_blog|industry_focus-707821
Jan 08, 2020 - Here we present three non-cancer therapeutic areas wherein pipeline developments are expected to garner a lot of interest in 2020.
0
Merck's Keytruda Misses an Important Lung Cancer Goal
https://www.fool.com/investing/2020/01/07/mercks-keytruda-misses-an-important-lung-cancer-en.aspx?source=iedfolrf0000001
Jan 07, 2020 - The star cancer immunotherapy missed an important endpoint during a study with small cell lung cancer.
0
Merck's Keytruda Misses One of Two Goals in Lung Cancer Study
http://www.zacks.com/stock/news/706462/mercks-keytruda-misses-one-of-two-goals-in-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-706462
Jan 07, 2020 - Merck's (MRK) phase III first-line SCLC study fails to meet one of the two primary endpoints. It signs an oncology collaboration with Taiho Pharmaceutical and Astex Pharmaceuticals.
0
AstraZeneca's Lynparza Gets FDA Nod for Pancreatic Cancer
http://www.zacks.com/stock/news/695998/astrazenecas-lynparza-gets-fda-nod-for-pancreatic-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-695998
Dec 31, 2019 - AstraZeneca (AZN) and Merck's Lynparza becomes the first PARP inhibitor to get approval for treating pancreatic cancer in the United States.
0
3 Dividend-Paying Large Cap Pharma Stocks to Consider for 2020
http://www.zacks.com/stock/news/690807/3-dividend-paying-large-cap-pharma-stocks-to-consider-for-2020?cid=CS-ZC-FT-stocks_in_the_news|investment_ideas-690807
Dec 27, 2019 - The stock market continued its end of the year rally Friday as the three major indices all hit new intraday highs.
0
ImmunoGen Lead Drug Gets Nod for Accelerated Approval Pathway (Revised)
http://www.zacks.com/stock/news/685596/immunogen-lead-drug-gets-nod-for-accelerated-approval-pathway-revised?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-685596
Dec 24, 2019 - FDA approves a new pivotal study to support accelerated approval pathway for ImmunoGen's (IMGN) ovarian cancer candidate, mirvetuximab soravtansine.
0